Recorded Chinese product: 氯唑沙宗片氯唑沙宗片

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

氯唑沙宗是一种在国家药监局注册认定的药品。该药品含有氯唑沙宗-80dafa75等成分。

该药品关联的活性成分包括:氯唑沙宗Lvzuo Shazong。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:太仓制药厂Chinese legal name: 太仓制药厂。

您可以探索含有相同成分的其他药品:氯唑沙宗-80dafa75成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 氯唑沙宗片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).

Active ingredients associated with this product: 氯唑沙宗Lvzuo Shazong.

Manufacturers recorded for this product: 太仓制药厂Chinese legal name: 太仓制药厂.

Explore other medicines containing the same ingredient: 氯唑沙宗 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 氯唑沙宗片Recorded Chinese product: 氯唑沙宗片
  • 剂型Dosage form: 片剂Tablets
  • 规格Specification: 0.2g0.2 g

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 太仓制药厂Chinese legal name: 太仓制药厂

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H32023070

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
  • 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H32023070

Manufacturer

Chinese legal name: 太仓制药厂 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

English translation unavailable. The original Chinese source label remains available below.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字H32023070

生产企业

太仓制药厂(国产)

适应症

本品适用于各种急性、慢性软组织(肌肉、韧带、筋膜)扭伤、挫伤,运动后肌肉酸痛、肌肉劳损所引起的疼痛、由中枢神经病变引起的肌肉痉挛,以及慢性筋膜炎等。

用法用量

饭后服用。成人每次0.2~0.4g(1~2片),每日3次,症状严重者可酌情加量,儿童遵医嘱。

不良反应

以恶心等消化道症状为主,其次是头昏、头晕、嗜睡等神经系统反应,不良反应一般较轻微,可自行消失或在停药后缓解。

禁忌

对氯唑沙宗过敏者禁用。

注意事项

肝、肾功能损害者慎用。与酚噻嗪类、巴比妥酸类衍生物等中枢抑制剂及单胺氧化酶抑制剂合用时,应减少本品用量。

贮藏

密封保存

规格

0.2g

证据Evidence

  • 批准文号: 国药准字H32023070
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.